drug
T-Cell Therapy
Preclinicalupdated 5mo agoby Eureka Therapeutics Inc
Preclinicalcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying T-Cell Therapy
- phase1Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
- phase3Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
- phase1NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
- phase2CAR-T Cell Therapy Targeting to CD19 for R/R ALL
- phase2Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- phase2Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
- phase2Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
- phase2Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
News(10)
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 3d ago
- STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patientsThe FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.stat · 3mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 4mo ago
- FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell LymphomaThe FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.onclive · 4mo ago
- Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSLAshley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.onclive · 4mo ago
- Consensus Recommendations Address Key Controversies in Lymphoma ManagementAlexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.onclive · 4mo ago
- BRUIN CLL-321 Trial Impact and Treatment SelectionExperts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.onclive · 4mo ago
- Biomarker-Driven Treatment Decisions and Managing Progression After Frontline ImmunotherapyUpfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.onclive · 4mo ago
- Dr Postow on an Ideal Post-ICI Monitoring Framework in MelanomaMichael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.onclive · 4mo ago
- Dr Postow on the Timing of Delayed or Re-Emergent irAEs in MelanomaMichael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that